Wednesday, February 10, 2010, 4:54pm SGT - The Singapore stock market closes in 6 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Durect Corp. (DRRX)

At 5:00AM SGT: 2.01 USD   0.00 (0.00%)  
 MORE ON DRRX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Durect Corporation (NGM:DRRX) Delayed quote dataEdit
Last Trade:2.01 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:2.01
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:4.13
Day's Range:N/A - N/A
52wk Range:1.40 - 3.18
Volume:0
Avg Vol (3m):178,075
Market Cap:174.36M
P/E (ttm):N/A
EPS (ttm):-0.49
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add DRRX to Portfolio   Download Data

 HEADLINES 
•DURECT CORP Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Jan 29)
•DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 20)
•DURECT Corporation Conference Call to Discuss POSIDUR Phase 3 Program scheduled for 11:00 am ET today
CCBN (Wed, Jan 20)
•DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
PR Newswire (Tue, Jan 19)
•Build Your Fortune With These Winners
at Motley Fool (Thu, Jan 7)
•DURECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Dec 18)
•Durect: Pain anesthesia shows positive results
AP (Fri, Dec 18)
•DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical Program
PR Newswire (Thu, Dec 17)
•DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
PR Newswire (Tue, Nov 24)
•DURECT CORP Financials
EDGAR Online Financials (Fri, Nov 6)
More Headlines for DRRX...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.34
EPS Est (in 2 years) (Dec-10) :-0.30
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulation...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices